Alleged violations of the Controlled Substances Act could result in billions of dollars in penalties.
Alleged violations of the Controlled Substances Act could result in billions of dollars in penalties.
Initial insights from Healthesystems’ annual industry survey.
Vaccine candidates from Pfizer-BioNTech and Moderna received EUAs, as did the first at-home test that delivers results in 30 minutes, and two treatments for the virus.
Navigating the workers’ comp process can be daunting for patients, and empathy can go a long way in improving outcomes.
A new report explores how COVID-19 has impacted telemedicine, as well as opportunities for expansion.
Stakeholders will soon experience a streamlined digital process for managing claims.
Healthesystems’ Chief Medical Officer comments on the U.S. House’s approval of marijuana decriminalization.
Veklury is approved for hospitalized patients, while bamlanivimab is being investigated in mild-to-moderate cases of COVID-19.
Across the nation, not only is marijuana growing more accepted, but so are other drugs like psilocybin and MDMA.
Direct customer exposure is associated with a five-fold risk of infection, while less social distancing in the workplace is tied to depression and anxiety.
The election saw passage of a measure to exempt rideshare drivers from employee status, impacting benefits and more.
Join our VP of Clinical Services, Silvia Sacalis, for a digital presentation on employing empathy within workers’ comp programs on December 9th!
Even at recommended doses, benzodiazepine use can lead to misuse, abuse, and addiction.
User research indicates that patients face difficulty with the intake process, getting key claim information, and more.
The drug manufacturer is pleading guilty and paying out billions.
COVID-19 claim data through October 5th has been captured and broken down by industry, age, region, and more.
Learn how our pharmacists make a difference for injured worker patients, and what drives their hard work
Olinvyk injections and Qdolo oral solution are approved for the management of acute pain.
With the pandemic disrupting the healthcare system, how has workers’ comp been impacted?
Data from 26,000 claims finds that early physical therapy reduces costs and disability duration.
A wide-sweeping order on national telehealth policy requires federal agencies to begin making plans for change.
Data from nearly 12,000 COVID-19 claims breaks down coverage among industries, telemedicine insights, and more.
2020 has been a year of disruption, and we want to know what the industry thinks about COVID-19, telehealth, opioids, AI, and more!
The FDA recommends healthcare professionals co-prescribe the opioid overdose reversal drug with all opioid prescriptions.
Healthesystems’ VP of Clinical Services addresses COVID-19 disruptions to workers’ comp, along with helpful strategies
AMA hopes to shift from a crisis-reaction framework to a more holistic model that prevents overdose while helping pain patients receive care.
Beyond first responders and healthcare workers, essential workers including grocery store workers are now covered by workers’ comp.
With cases increasing as individuals return to work, injured workers face barriers to care, risk of infection, and more.
As complex claims continue to impact workers’ comp, our new article in WorkCompWire addresses the need for early warnings and clinical guidance.
Subcutaneous injections of the new biologic, adalimumab-fkjp, were approved for seven indications.
Strategies for anticipating and mitigating complex claim risks.
The AMA suggests that prescription medications are no longer a significant factor in the opioid epidemic, and that opioid prescription limits should change.
Arkansas and Louisiana enacted policies to protect businesses from civil liability stemming from COVID-19 exposure.
Data from 28 states years found that NSAIDs and dermatological agents are seeing growth in spending.
With opioid utilization decreasing, what concerns do other pain therapies pose?
With data from 36 states across 12 years, this report highlights the differences in prices paid for medical services across the nation.
Occupations are divided into risk categories where each category must utilize appropriate face coverings, masks, or respirators.
The National Safety Council discusses managing employee anxiety stemming from COVID-19 when returning to work.
Elyxyb (celecoxib) is an NSAID for the acute treatment of migraine with or without aura.
How comorbidities, fatigue, and mental health impact claims management.
The FDA allows emergency use in response to positive trials, but more research is needed.
A new study explores patients’ use of health services, the impact on medicine use, research activity, and more.
Many states expanded workers’ comp for COVID-19, but California casts a wider net.
New developments with diagnostic testing and the use of chloroquine and hydroxychloroquine.
Healthesystems’ AVP of Advocacy & Compliance discusses regulatory action related to COVID-19 with WorkCompWire.
The FDA, JAMA, and others think blood from those who recovered from COVID-19 could benefit those with the illness.
With frontline workers at risk, states are expanding coverage to healthcare workers, first responders, and other frontline workers.
Healthesystems’ VP of Clinical Services discusses population trends, non-opioid pain therapies, and comorbidities with WorkCompWire.
Healthesystems has created a developments webpage to track updates impacting workers’ comp.
Anjeso and a new Advil formulation target pain, while Nurtec™ and Vyepti™ target migraines.
Healthesystems collaborated with Risk & Insurance to survey 669 workers’ comp professionals on top trends and challenges.
A study of 41,000 adults finds that only treatment with buprenorphine or methadone reduced risk of overdose.
Several state workers’ comp programs are relaxing telehealth rules to promote social distancing.
Healthesystems’ AVP of Advocacy & Compliance discusses industry challenges, special initiatives, and more in a video spotlight.
A new seizure drug has been approved, and a nerve growth drug advances in clinical trials.
What will 2020 hold for marijuana acceptance, employee misclassification, formularies, and AI?
An analysis of 1.5 million claims found early physical therapy lowers odds of opioid use by 14%.
Testing positive for marijuana use could one day no longer prohibit employment.
With a flurry of opioid developments lately, what does the big picture look like?
Migraine, arthritis, and insomnia drug approvals, and a gabapentinoids safety warning.
